4MDS

Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and non-covalent nanomolar inhibitors with an induced-fit binding

Changes made to a PDB entry after its initial release are considered to be either ��major�� or ��minor��. The latest minor version of each major version is available as a file download. More information about the PDB versioning is available.

Version Number	Version Date	Version Type/Reason	Version Change	Revised CIF Category
1.0	2013-10-02	Initial release
1.1	2013-10-16		Database references
1.2	2013-11-06		Database references
1.3	2024-02-28		Data collection, Database references, Derived calculations	chem_comp_atom, chem_comp_bond, database_2, struct_ref_seq_dif, struct_site	Download

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.

Prepare Data

Validate Data

Deposit Data

Help and Resources

4MDS

Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and non-covalent nanomolar inhibitors with an induced-fit binding